Symphogen
Tine Ebstrup has a diverse work experience in the scientific and pharmaceutical field. Tine is currently working as a Senior Scientist at Symphogen since June 2022. Prior to this, they worked at LEO Pharma as a Principal Scientist from October 2020 to June 2022. Before joining LEO Pharma, they worked at Novo Nordisk where they held various roles including Senior Research Scientist from October 2014 to October 2020, Chemist Diabetes Finished Products Manufacturing Development from 2008 to 2014, and Regulatory Affairs Professional from 2007 to 2008. Tine started their career as a PHD Student at Risø National Laboratory from 2001 to 2004.
Tine Ebstrup completed their education in the field of biology. Tine started their academic journey at the University of Copenhagen, where they pursued a Cand. Scient degree from 1994 to 2001. Tine then furthered their studies at the University of Southern Denmark, known as Syddansk Universitet, from 2001 to 2004. Here, they obtained their Doctor of Philosophy (Ph.D.) in Biochemistry and Molecular Biology.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.